Drugs & Therapy Perspectives

, Volume 7, Issue 9, pp 10–13 | Cite as

Guidelines can reduce the risk of clozapine-induced agranulocytosis

Drug Reactions and Interactions


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mendelowitz AJ, Gerson SL, Alvir JMaJ, et al. Clozapine-induced agranulocytosis. Risk factors, monitoring and management. CNS Drugs 1995; 4(6): 412–21Google Scholar
  2. 2.
    Balon R, Berchov R. Hematological side effects of psychotropic drugs. Psychosomatics 1986; 27: 119–27PubMedCrossRefGoogle Scholar
  3. 3.
    Jalenques I. Drug-resistant schizophrenia. Treatment options. CNS Drugs 1996; 5(1): 8–23Google Scholar
  4. 4.
    Antipsychotic selection depends on individual response and tolerability. Drug Ther Perspect 19 Jul 1993; 2(1): 8–11CrossRefGoogle Scholar
  5. 5.
    Clozapine: indications are defined by clinical not economic criteria. Drug Ther Perspect 22 Nov 1993; 2(10): 5–7CrossRefGoogle Scholar
  6. 6.
    Alvir JMaJ, Lieberman JA, Safferman AZ. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7PubMedCrossRefGoogle Scholar
  7. 7.
    Alvir JMaJ, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55 (9 Suppl. b): 137–8Google Scholar
  8. 8.
    Alvir JMaJ, Lieberman JA, Safferman AZ. Do white-cell count spikes predict agranulocytosis in clozapine recipients. Psychopharmacol Bull 1995; 31: 311–4PubMedGoogle Scholar
  9. 9.
    Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945–8PubMedCrossRefGoogle Scholar
  10. 10.
    Honigfeld G. Effects of the clozapine national registry system on the incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52–56PubMedGoogle Scholar
  11. 11.
    Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55 (9 Suppl. b): 139–42Google Scholar
  12. 12.
    Gerson SL. Clozapine: deciphering the risks [editorial]. N Engl J Med 1993: 204–5Google Scholar
  13. 13.
    Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991; 5: 21–33Google Scholar
  14. 14.
    Safferman AZ, Lieberman JA, Alvir JMaJ, et al. Rechallenge in clozapine-induced agranulocytosis [letter]. Lancet 1992; 340: 1097Google Scholar

Copyright information

© Adis lnternational Limited 1996

Personalised recommendations